Skip to main content
SpringerLink
Log in

Antagonism of miRNA-21 Sensitizes Human Gastric Cancer Cells to Paclitaxel

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

The development of drug resistance has largely limited the clinical outcome of anti-cancer treatment. Recent work has highlighted the involvement of non-coding RNAs, microRNAs (miRNAs), in cancer development. The present study aimed to investigate the role of miR-21 in the development of drug resistance to paclitaxel in gastric cancer cells. Our study found that the expression of miR-21 upregulated in the paclitaxel resistant cell line SGC7901/paclitaxel compared to its parental line SGC7901. Moreover, over-expression of miR-21 significantly decreased antiproliferative effects and apoptosis induced by paclitaxel, while knockdown of miR-21 dramatically increased antiproliferative effects and apoptosis induction by paclitaxel. Moreover, our results demonstrated that miR-21 may modulate the sensitivity to PTX, at least in part, by regulating the expression of P-glycoprotein.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Meng, F., Henson, R., Lang, M., Wehbe, H., Maheshwari, S., Mendell, J. T., et al. (2006). Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology, 130, 2113–2129.

    Article  CAS  PubMed  Google Scholar 

  2. Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011). Global cancer statistics. CA: A Cancer Journal for Clinicians, 61, 69–90.

    Google Scholar 

  3. Xie, Z., Cao, L., & Zhang, J. (2013). miR-21 modulates paclitaxel sensitivity and hypoxia-inducible factor-1alpha expression in human ovarian cancer cells. Oncology Letters, 6, 795–800.

    CAS  PubMed Central  PubMed  Google Scholar 

  4. Wu, G., Qin, X. Q., Guo, J. J., Li, T. Y., & Chen, J. H. (2014). AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel. International Journal of Clinical and Experimental Pathology, 7, 1449–1458.

    PubMed Central  PubMed  Google Scholar 

  5. Huang, H., Han, Y., Gao, J., Feng, J., Zhu, L., Qu, L., et al. (2013). High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients. Medical Oncology, 30, 748.

    Article  PubMed  Google Scholar 

  6. Yuan, M., Yang, Y., Lv, W., Song, Z., & Zhong, H. (2014). Paclitaxel combined with capecitabine as first-line chemotherapy for advanced or recurrent gastric cancer. Oncology Letters, 8, 351–354.

    CAS  PubMed Central  PubMed  Google Scholar 

  7. Yoshino, S., Furuya, T., Shimizu, R., Ozasa, H., Nishimura, T., Fukuda, S., et al. (2013). Combination phase II study of weekly paclitaxel and 5′-DFUR for unresectable or recurrent gastric cancer. Anticancer Research, 33, 2629–2633.

    CAS  PubMed  Google Scholar 

  8. Wang, X., Wang, M. L., Zhou, L. Y., Lu, X. Y., Yang, J. F., & Yu, H. G. (2013). Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer. Clinical and Translational Oncology, 15, 836–842.

    Article  CAS  PubMed  Google Scholar 

  9. Kadokura, M., Iwasa, S., Honma, Y., Kato, K., Hamaguchi, T., Yamada, Y., et al. (2013). Weekly paclitaxel as second-line chemotherapy in Japanese patients with advanced gastric cancer. Anticancer Research, 33, 4547–4552.

    CAS  PubMed  Google Scholar 

  10. Ando, T., Hosokawa, A., Kajiura, S., Itaya, Y., Ueda, A., Fujinami, H., et al. (2012). Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapy. Gastric Cancer, 15, 427–432.

    Article  CAS  PubMed  Google Scholar 

  11. Sasaki, Y., Nishina, T., Yasui, H., Goto, M., Muro, K., Tsuji, A., et al. (2014). Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Science, 105, 812–817.

    Article  CAS  PubMed  Google Scholar 

  12. Kong, Y. W., Ferland-McCollough, D., Jackson, T. J., & Bushell, M. (2012). microRNAs in cancer management. The Lancet Oncology, 13, e249–e258.

    Article  CAS  PubMed  Google Scholar 

  13. Flynt, A. S., & Lai, E. C. (2008). Biological principles of microRNA-mediated regulation: Shared themes amid diversity. Nature Reviews Genetics, 9, 831–842.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Carthew, R. W., & Sontheimer, E. J. (2009). Origins and mechanisms of miRNAs and siRNAs. Cell, 136, 642–655.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Ren, Y., Zhou, X., Mei, M., Yuan, X. B., Han, L., Wang, G. X., et al. (2010). MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer, 10, 27.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Volinia, S., Calin, G. A., Liu, C. G., Ambs, S., Cimmino, A., Petrocca, F., et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America, 103, 2257–2261.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Chan, S. H., Wu, C. W., Li, A. F., Chi, C. W., & Lin, W. C. (2008). miR-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Research, 28, 907–911.

    PubMed  Google Scholar 

  18. Zhang, Z., Li, Z., Gao, C., Chen, P., Chen, J., Liu, W., et al. (2008). miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Laboratory Investigation: A Journal of Technical Methods and Pathology, 88, 1358–1366.

    Article  CAS  Google Scholar 

  19. Li, Z., Hu, S., Wang, J., Cai, J., Xiao, L., Yu, L., & Wang, Z. (2010). MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecologic Oncology, 119, 125–130.

    Article  CAS  PubMed  Google Scholar 

  20. Bao, L., Yan, Y., Xu, C., Ji, W., Shen, S., Xu, G., et al. (2013). MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. Cancer Letters, 337, 226–236.

    Article  CAS  PubMed  Google Scholar 

  21. Chen, C., Ridzon, D. A., Broomer, A. J., Zhou, Z., Lee, D. H., Nguyen, J. T., et al. (2005). Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Research, 33, e179.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods, 25, 402–408.

    Article  CAS  PubMed  Google Scholar 

  23. Huang, S., Chen, M., Shen, Y., Shen, W., Guo, H., Gao, Q., & Zou, X. (2012). Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Letters, 315, 198–205.

    Article  CAS  PubMed  Google Scholar 

  24. Goda, K., Bacso, Z., & Szabo, G. (2009). Multidrug resistance through the spectacle of P-glycoprotein. Current Cancer Drug Targets, 9, 281–297.

    Article  CAS  PubMed  Google Scholar 

  25. Roberti, A., La Sala, D., & Cinti, C. (2006). Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: Current views and new therapeutic prospective. Journal of Cellular Physiology, 207, 571–581.

    Article  CAS  PubMed  Google Scholar 

  26. Selimovic, D., Hassan, M., Haikel, Y., & Hengge, U. R. (2008). Taxol-induced mitochondrial stress in melanoma cells is mediated by activation of c-Jun N-terminal kinase (JNK) and p38 pathways via uncoupling protein 2. Cellular Signalling, 20, 311–322.

    Article  CAS  PubMed  Google Scholar 

  27. Yu, J., Gao, J., Lu, Z., Li, Y., & Shen, L. (2012). Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine. Medical Oncology, 29, 3029–3034.

    Article  CAS  PubMed  Google Scholar 

  28. Zhang, C., Awasthi, N., Schwarz, M. A., & Schwarz, R. E. (2013). The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer. International Journal of Oncology, 43, 1627–1635.

    CAS  PubMed Central  Google Scholar 

  29. Haruki, K., Shiba, H., Fujiwara, Y., Furukawa, K., Iwase, R., Uwagawa, T., et al. (2013). Inhibition of nuclear factor-kappaB enhances the antitumor effect of paclitaxel against gastric cancer with peritoneal dissemination in mice. Digestive Diseases and Sciences, 58, 123–131.

    Article  CAS  PubMed  Google Scholar 

  30. Le, X. F., & Bast, R. C., Jr. (2011). Src family kinases and paclitaxel sensitivity. Cancer Biology and Therapy, 12, 260–269.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Qiu, H., Yashiro, M., Zhang, X., Miwa, A., & Hirakawa, K. (2011). A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells. Cancer Letters, 307, 47–52.

    Article  CAS  PubMed  Google Scholar 

  32. Mi, Y. J., Liang, Y. J., Huang, H. B., Zhao, H. Y., Wu, C. P., Wang, F., et al. (2010). Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Research, 70, 7981–7991.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Sanui, A., Yotsumoto, F., Tsujioka, H., Fukami, T., Horiuchi, S., Shirota, K., et al. (2010). HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer. Anticancer Research, 30, 3143–3149.

    CAS  PubMed  Google Scholar 

  34. Gutierrez-Gonzalez, A., Belda-Iniesta, C., Bargiela-Iparraguirre, J., Dominguez, G., Garcia Alfonso, P., Perona, R., & Sanchez-Perez, I. (2013). Targeting Chk2 improves gastric cancer chemotherapy by impairing DNA damage repair. Apoptosis: An International Journal on Programmed Cell Death, 18, 347–360.

    Article  CAS  Google Scholar 

  35. Huang, D., Wang, H., Liu, R., Li, H., Ge, S., Bai, M., et al. (2014). miRNA27a is a biomarker for predicting chemosensitivity and prognosis in metastatic or recurrent gastric cancer. Journal of Cellular Biochemistry, 115, 549–556.

    Article  CAS  PubMed  Google Scholar 

  36. Liu, X., Ru, J., Zhang, J., Zhu, L. H., Liu, M., Li, X., & Tang, H. (2013). miR-23a targets interferon regulatory factor 1 and modulates cellular proliferation and paclitaxel-induced apoptosis in gastric adenocarcinoma cells. PLoS One, 8, e64707.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. Wu, H., Huang, M., Lu, M., Zhu, W., Shu, Y., Cao, P., & Liu, P. (2013). Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel. Cancer Chemotherapy and Pharmacology, 71, 1159–1171.

    Article  CAS  PubMed  Google Scholar 

  38. Kovalchuk, O., Filkowski, J., Meservy, J., Ilnytskyy, Y., Tryndyak, V. P., Chekhun, V. F., & Pogribny, I. P. (2008). Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Molecular Cancer Therapeutics, 7, 2152–2159.

    Article  CAS  PubMed  Google Scholar 

  39. Pan, Y. Z., Morris, M. E., & Yu, A. M. (2009). MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Molecular Pharmacology, 75, 1374–1379.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Miller, T. E., Ghoshal, K., Ramaswamy, B., Roy, S., Datta, J., Shapiro, C. L., et al. (2008). MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. The Journal of Biological Chemistry, 283, 29897–29903.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Yang, S. M., Huang, C., Li, X. F., Yu, M. Z., He, Y., & Li, J. (2013). miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology, 306, 162–168.

    Article  CAS  PubMed  Google Scholar 

  42. Breier, A., Barancik, M., Sulova, Z., & Uhrik, B. (2005). P-glycoprotein—implications of metabolism of neoplastic cells and cancer therapy. Current Cancer Drug Targets, 5, 457–468.

    Article  CAS  PubMed  Google Scholar 

  43. Kim, H. G., Hien, T. T., Han, E. H., Hwang, Y. P., Choi, J. H., Kang, K. W., et al. (2011). Metformin inhibits P-glycoprotein expression via the NF-kappaB pathway and CRE transcriptional activity through AMPK activation. British Journal of Pharmacology, 162, 1096–1108.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Bourguignon, L. Y., Spevak, C. C., Wong, G., Xia, W., & Gilad, E. (2009). Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. The Journal of Biological Chemistry, 284, 26533–26546.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

The research is supported by Innovation Fund of Xinjiang Medical University (Fund No. XJC201264) and Innovation Fund of The Third Affiliated Hospital (Xinjiang Tumor Hospital), Xinjiang Medical University (Fund No. SLCX0304).

Author information

Authors and Affiliations

  1. Department of Gastroenteropathy Surgery, The Third Affiliated Hospital (Xinjiang Tumor Hospital), Xinjiang Medical University, Urumqi, 830011, Xinjiang, China

    Bo Jin & Haijiang Wang

  2. Department of Anesthesiology, The Third Affiliated Hospital (Xinjiang Tumor Hospital), Xinjiang Medical University, Urumqi, 830011, Xinjiang, China

    Yanping Liu

Authors
  1. Bo Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yanping Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Haijiang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Bo Jin or Yanping Liu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jin, B., Liu, Y. & Wang, H. Antagonism of miRNA-21 Sensitizes Human Gastric Cancer Cells to Paclitaxel. Cell Biochem Biophys 72, 275–282 (2015). https://doi.org/10.1007/s12013-014-0450-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12013-014-0450-2

Keywords

Search

Navigation